A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond

Highlights • HER2 positive gastric cancer is associated with a specific phenotype. • Reliable HER2 testing is mandatory for the correct use of anti-HER2 treatment. • We review present HER2 diagnosis and directed therapies in gastric cancer. • Future strategies for HER2 gastric cancer treatment are d...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer letters Vol. 351; no. 1; pp. 30 - 40
Main Authors:	Gomez-Martín, Carlos, Lopez-Rios, Fernando, Aparicio, Jorge, Barriuso, Jorge, García-Carbonero, Rocio, Pazo, Roberto, Rivera, Fernando, Salgado, Mercedes, Salud, Antonieta, Vázquez-Sequeiros, Enrique, Lordick, Florian
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier Ireland Ltd 28-08-2014 Elsevier Limited
Subjects:	Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - secondary Animals Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Biomarkers, Tumor - metabolism Biopsy Chemotherapy Clinical Trials as Topic Gastric cancer Hematology, Oncology and Palliative Medicine HER2 Humans Metastasis Prognosis Receptor, ErbB-2 - metabolism Response rates Review Stomach Neoplasms - drug therapy Stomach Neoplasms - metabolism Stomach Neoplasms - pathology Studies Trastuzumab Europe Review HER2 Gastric cancer Trastuzumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Highlights • HER2 positive gastric cancer is associated with a specific phenotype. • Reliable HER2 testing is mandatory for the correct use of anti-HER2 treatment. • We review present HER2 diagnosis and directed therapies in gastric cancer. • Future strategies for HER2 gastric cancer treatment are discussed.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2014.05.019